OPHLF - Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
8-2, Kyutaromachi 1-chome
Chuo-ku
Osaka 541-8564
Japan
81 6 6263 5670
https://www.ono-pharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Gyo Sagara | CEO, Pres & Representative Director | N/A | N/A | 1958 |
| Mr. Shozo Matsuoka Ph.D. | Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA | N/A | N/A | N/A |
| Yukio Tani | Corp. Exec. Officer & Head of Corp. Communications | N/A | N/A | N/A |
| Katsuji Teranishi | Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div. | N/A | N/A | N/A |
| Mr. Isao Ono | Exec. Officer, Director of Corp. Research & Director | N/A | N/A | 1959 |
| Mr. Hiroshi Ichikawa | Corp. Officer & Sr. Director of Medical External Affairs | N/A | N/A | N/A |
| Mr. Toichi Takino Ph.D. | Sr. Exec. Officer, Exec. Director of Discovery & Research and Director | N/A | N/A | 1968 |
| Mr. Toshihiro Tsujinaka | Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director | N/A | N/A | 1964 |
| Hiromu Habashita Ph.D. | Corp. Officer and Deputy Exec. Director of Discovery & Research Division | N/A | N/A | N/A |
| Kiyoaki Idemitsu | Exec. Officer, Exec. Director of Clinical Devel. & Director | N/A | N/A | 1964 |
Description
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
Corporate governance
Ono Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 2; Compensation: 1.
